Parenteral Antibiotics Market Forecasts to 2032 – Global Analysis By Drug Class (Penicillins, Macrolides, Cephalosporins, Glycopeptides, Carbapenems, Aminoglycosides, and Other Drug Classes), Spectrum of Activity, Formulation Type, Route of Administration
Description
According to Stratistics MRC, the Global Parenteral Antibiotics Market is accounted for $25.74 billion in 2025 and is expected to reach $39.48 billion by 2032 growing at a CAGR of 6.3% during the forecast period. Parenteral antibiotics refer to drugs given outside the digestive system, commonly via intravenous, intramuscular, or subcutaneous injection. They are preferred for urgent treatment, cases where oral intake is not feasible, or when gastrointestinal absorption is inadequate. This method delivers the medication directly into the bloodstream, providing rapid action, greater bioavailability, and effective management of serious or widespread infections requiring immediate intervention.
According to a study published in National Canter for Biotechnology Information (NCBI) in November 2021, in Nepal, the total defined daily dose (DDD) of parenteral antibiotics reached 48,947.7 in 2019 with an increase of 23% from 39,639.7 in 2017.
Market Dynamics:
Driver:
Growing antimicrobial resistance (AMR)
As pathogens evolve and become resistant to conventional treatments, healthcare providers are turning to injectable formulations for faster and more effective outcomes. This trend is especially pronounced in hospital settings where multidrug-resistant infections are prevalent. Technological advancements in drug delivery systems and formulation science are enhancing the efficacy of parenteral antibiotics. The rise of precision medicine and pathogen-specific therapies is further boosting market growth. Global health agencies are also prioritizing AMR mitigation, driving investment in novel antibiotic classes and stewardship programs.
Restraint:
High cost of development and commercialization
Extensive clinical trials, stringent safety protocols, and compliance with global standards like FDA and EMA regulations contribute to prolonged timelines and elevated costs. Incorporating advanced technologies such as liposomal delivery and extended-release mechanisms adds complexity to the approval process. Smaller pharmaceutical firms often face resource constraints, limiting their ability to innovate or scale production. Additionally, the need for cold chain logistics and sterile packaging increases operational expenses. These factors collectively hinder rapid market entry and slow down the pace of therapeutic innovation.
Opportunity:
Growing outpatient parenteral antibiotic therapy (OPAT)
The expansion of outpatient parenteral antibiotic therapy (OPAT) is unlocking new growth avenues for the market. OPAT enables patients to receive intravenous antibiotics outside hospital settings, reducing inpatient burden and healthcare costs. Advances in portable infusion devices and remote monitoring technologies are making OPAT more accessible and safer. Healthcare systems are increasingly adopting decentralized care models, with home-based treatments gaining traction. Reimbursement reforms and clinical guidelines are supporting OPAT integration into mainstream care. This shift is driving demand for user-friendly, stable, and long-acting parenteral antibiotic formulations tailored for outpatient use.
Threat:
Increased competition from generics
Patent expirations and regulatory incentives for biosimilar development are accelerating generic entry. While generics improve accessibility, they also compress profit margins for originator companies. Technological parity in manufacturing and formulation is narrowing the differentiation gap. Emerging markets are witnessing a surge in local generic production, intensifying competitive dynamics. To maintain market share, innovators must invest in lifecycle management strategies, such as reformulations and combination therapies.
Covid-19 Impact:
The COVID-19 pandemic significantly disrupted the parenteral antibiotics landscape, altering demand patterns and supply chain operations. Elective procedures were postponed, reducing hospital-based antibiotic usage, while ICU admissions surged, increasing demand for broad-spectrum injectables. Manufacturing delays and global logistics bottlenecks led to temporary shortages of critical antibiotics. However, the crisis accelerated digital health adoption, including remote prescribing and telemedicine-based OPAT programs. Regulatory bodies introduced emergency pathways to fast-track approvals and ensure drug availability. Post-pandemic recovery is now focused on building resilient supply chains and expanding decentralized treatment models.
The penicillinssegment is expected to be the largest during the forecast period
The penicillinssegment is expected to account for the largest market share during the forecast period, due to its broad-spectrum efficacy and established clinical utility. These antibiotics are widely used in treating respiratory, skin, and urinary tract infections, especially in inpatient settings. Continuous improvements in formulation stability and dosing convenience are reinforcing their market leadership. The development of extended-spectrum penicillins and beta-lactamase inhibitor combinations is enhancing resistance management. Hospitals favor penicillins for their safety profile and cost-effectiveness, particularly in high-volume treatment scenarios. Emerging trends include dual-drug regimens and integration into OPAT protocols.
The ambulatory surgical centerssegment is expected to have the highest CAGR during the forecast period
Over the forecast period, the ambulatory surgical centerssegment is predicted to witness the highest growth rate, driven by the rise in outpatient procedures. ASCs are increasingly performing complex surgeries that require perioperative antibiotic prophylaxis. Integration of smart infusion systems and cloud-based inventory tracking is streamlining antibiotic administration. Favorable reimbursement policies and shorter patient stays are boosting ASC utilization. The shift toward minimally invasive techniques is increasing demand for rapid-acting injectable antibiotics. Innovations in compact antibiotic kits and single-dose packaging are tailored for ASC workflows.
Region with largest share:
During the forecast period, the Asia Pacificregion is expected to hold the largest market share, supported by expanding healthcare infrastructure and rising infection rates. Countries like China, India, and Indonesia are investing in hospital capacity and antibiotic manufacturing capabilities. Government initiatives promoting local production and antimicrobial stewardship are fueling market expansion. The region is witnessing rapid adoption of injectable therapies in both urban and rural settings. Strategic collaborations between global pharmaceutical firms and regional players are enhancing distribution and technology transfer. Emerging trends include AI-assisted diagnostics and mobile OPAT units in underserved areas.
Region with highest CAGR:
Over the forecast period, the North Americaregion is anticipated to exhibit the highest CAGR, driven by technological innovation and robust healthcare spending. The U.S. and Canada are leading in the development of novel parenteral antibiotic formulations, including liposomal and nanoparticle-based injectables. Regulatory agencies are streamlining approval pathways for critical antibiotics, encouraging faster market entry. Hospitals are integrating electronic prescribing and smart infusion pumps to optimize antibiotic delivery. The region benefits from strong reimbursement frameworks and high awareness of AMR challenges. As personalized medicine and outpatient care expand, North America remains at the forefront of antibiotic innovation.
Key players in the market
Some of the key players in Parenteral Antibiotics Market include Pfizer Inc., Sandoz, Merck & Co., Inc., Spero Therapeutics, Johnson & Johnson, AstellasPharma Inc., GlaxoSmithKline plc, Entasis Therapeutics, Sanofi, F. Hoffmann-La Roche Ltd, Novartis AG, Bristol-Myers Squibb, Bayer AG, Eli Lilly and Company, and Abbott Laboratories.
Key Developments:
In September2025, Pfizer Inc. and Metsera, Inc. announced the companies have entered into a definitive agreement under which Pfizer will acquire Metsera, a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases. The acquisition brings deep expertise and a portfolio of differentiated oral and injectable incretin, non-incretin and combination therapy candidates with potential best-in-class efficacy and safety profiles.
In February2025, Shedd Aquarium and global healthcare company Abbott are announcing one of Shedd’s largest corporate gifts in recent history a $10 million pledge from Abbott and Abbott's philanthropic foundation, Abbott Fund. The investment cements the longstanding partnership between Shedd, Abbott, and Abbott Fund to enrich the cultural, educational and environmental fabric of Chicago and spark passion for protecting the ocean environment.
Drug Classes Covered:
• Penicillins
• Macrolides
• Cephalosporins
• Glycopeptides
• Carbapenems
• Aminoglycosides
• Other Drug Classes
Spectrum of Activities Covered:
• Broad-Spectrum Antibiotics
• Narrow-Spectrum Antibiotics
Formulation Types Covered:
• Single-Dose Vials
• Multi-Dose Vials
• Infusion Bags
• Pre-filled Syringes
Route of Administrations Covered:
• Intravenous (IV)
• Subcutaneous (SC)
• Intramuscular (IM)
Indications Covered:
• Respiratory Infections
• Urinary Tract Infections
• Skin and Soft Tissue Infections
• Hospital-Acquired Infections
• Intra-abdominal Infections
• Surgical Site Infections
• Sepsis and Bloodstream Infections
• Other Applications
End Users Covered:
• Hospitals
• Home Healthcare
• Specialty Clinics
• Ambulatory Surgical Centers
• Other End Users
Regions Covered:
• North America US Canada Mexico
• Europe Germany UK Italy France Spain Rest of Europe
• Asia Pacific Japan China India Australia New Zealand South Korea Rest of Asia Pacific
• South America Argentina Brazil Chile Rest of South America
• Middle East & Africa Saudi Arabia UAE Qatar South Africa Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
According to a study published in National Canter for Biotechnology Information (NCBI) in November 2021, in Nepal, the total defined daily dose (DDD) of parenteral antibiotics reached 48,947.7 in 2019 with an increase of 23% from 39,639.7 in 2017.
Market Dynamics:
Driver:
Growing antimicrobial resistance (AMR)
As pathogens evolve and become resistant to conventional treatments, healthcare providers are turning to injectable formulations for faster and more effective outcomes. This trend is especially pronounced in hospital settings where multidrug-resistant infections are prevalent. Technological advancements in drug delivery systems and formulation science are enhancing the efficacy of parenteral antibiotics. The rise of precision medicine and pathogen-specific therapies is further boosting market growth. Global health agencies are also prioritizing AMR mitigation, driving investment in novel antibiotic classes and stewardship programs.
Restraint:
High cost of development and commercialization
Extensive clinical trials, stringent safety protocols, and compliance with global standards like FDA and EMA regulations contribute to prolonged timelines and elevated costs. Incorporating advanced technologies such as liposomal delivery and extended-release mechanisms adds complexity to the approval process. Smaller pharmaceutical firms often face resource constraints, limiting their ability to innovate or scale production. Additionally, the need for cold chain logistics and sterile packaging increases operational expenses. These factors collectively hinder rapid market entry and slow down the pace of therapeutic innovation.
Opportunity:
Growing outpatient parenteral antibiotic therapy (OPAT)
The expansion of outpatient parenteral antibiotic therapy (OPAT) is unlocking new growth avenues for the market. OPAT enables patients to receive intravenous antibiotics outside hospital settings, reducing inpatient burden and healthcare costs. Advances in portable infusion devices and remote monitoring technologies are making OPAT more accessible and safer. Healthcare systems are increasingly adopting decentralized care models, with home-based treatments gaining traction. Reimbursement reforms and clinical guidelines are supporting OPAT integration into mainstream care. This shift is driving demand for user-friendly, stable, and long-acting parenteral antibiotic formulations tailored for outpatient use.
Threat:
Increased competition from generics
Patent expirations and regulatory incentives for biosimilar development are accelerating generic entry. While generics improve accessibility, they also compress profit margins for originator companies. Technological parity in manufacturing and formulation is narrowing the differentiation gap. Emerging markets are witnessing a surge in local generic production, intensifying competitive dynamics. To maintain market share, innovators must invest in lifecycle management strategies, such as reformulations and combination therapies.
Covid-19 Impact:
The COVID-19 pandemic significantly disrupted the parenteral antibiotics landscape, altering demand patterns and supply chain operations. Elective procedures were postponed, reducing hospital-based antibiotic usage, while ICU admissions surged, increasing demand for broad-spectrum injectables. Manufacturing delays and global logistics bottlenecks led to temporary shortages of critical antibiotics. However, the crisis accelerated digital health adoption, including remote prescribing and telemedicine-based OPAT programs. Regulatory bodies introduced emergency pathways to fast-track approvals and ensure drug availability. Post-pandemic recovery is now focused on building resilient supply chains and expanding decentralized treatment models.
The penicillinssegment is expected to be the largest during the forecast period
The penicillinssegment is expected to account for the largest market share during the forecast period, due to its broad-spectrum efficacy and established clinical utility. These antibiotics are widely used in treating respiratory, skin, and urinary tract infections, especially in inpatient settings. Continuous improvements in formulation stability and dosing convenience are reinforcing their market leadership. The development of extended-spectrum penicillins and beta-lactamase inhibitor combinations is enhancing resistance management. Hospitals favor penicillins for their safety profile and cost-effectiveness, particularly in high-volume treatment scenarios. Emerging trends include dual-drug regimens and integration into OPAT protocols.
The ambulatory surgical centerssegment is expected to have the highest CAGR during the forecast period
Over the forecast period, the ambulatory surgical centerssegment is predicted to witness the highest growth rate, driven by the rise in outpatient procedures. ASCs are increasingly performing complex surgeries that require perioperative antibiotic prophylaxis. Integration of smart infusion systems and cloud-based inventory tracking is streamlining antibiotic administration. Favorable reimbursement policies and shorter patient stays are boosting ASC utilization. The shift toward minimally invasive techniques is increasing demand for rapid-acting injectable antibiotics. Innovations in compact antibiotic kits and single-dose packaging are tailored for ASC workflows.
Region with largest share:
During the forecast period, the Asia Pacificregion is expected to hold the largest market share, supported by expanding healthcare infrastructure and rising infection rates. Countries like China, India, and Indonesia are investing in hospital capacity and antibiotic manufacturing capabilities. Government initiatives promoting local production and antimicrobial stewardship are fueling market expansion. The region is witnessing rapid adoption of injectable therapies in both urban and rural settings. Strategic collaborations between global pharmaceutical firms and regional players are enhancing distribution and technology transfer. Emerging trends include AI-assisted diagnostics and mobile OPAT units in underserved areas.
Region with highest CAGR:
Over the forecast period, the North Americaregion is anticipated to exhibit the highest CAGR, driven by technological innovation and robust healthcare spending. The U.S. and Canada are leading in the development of novel parenteral antibiotic formulations, including liposomal and nanoparticle-based injectables. Regulatory agencies are streamlining approval pathways for critical antibiotics, encouraging faster market entry. Hospitals are integrating electronic prescribing and smart infusion pumps to optimize antibiotic delivery. The region benefits from strong reimbursement frameworks and high awareness of AMR challenges. As personalized medicine and outpatient care expand, North America remains at the forefront of antibiotic innovation.
Key players in the market
Some of the key players in Parenteral Antibiotics Market include Pfizer Inc., Sandoz, Merck & Co., Inc., Spero Therapeutics, Johnson & Johnson, AstellasPharma Inc., GlaxoSmithKline plc, Entasis Therapeutics, Sanofi, F. Hoffmann-La Roche Ltd, Novartis AG, Bristol-Myers Squibb, Bayer AG, Eli Lilly and Company, and Abbott Laboratories.
Key Developments:
In September2025, Pfizer Inc. and Metsera, Inc. announced the companies have entered into a definitive agreement under which Pfizer will acquire Metsera, a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases. The acquisition brings deep expertise and a portfolio of differentiated oral and injectable incretin, non-incretin and combination therapy candidates with potential best-in-class efficacy and safety profiles.
In February2025, Shedd Aquarium and global healthcare company Abbott are announcing one of Shedd’s largest corporate gifts in recent history a $10 million pledge from Abbott and Abbott's philanthropic foundation, Abbott Fund. The investment cements the longstanding partnership between Shedd, Abbott, and Abbott Fund to enrich the cultural, educational and environmental fabric of Chicago and spark passion for protecting the ocean environment.
Drug Classes Covered:
• Penicillins
• Macrolides
• Cephalosporins
• Glycopeptides
• Carbapenems
• Aminoglycosides
• Other Drug Classes
Spectrum of Activities Covered:
• Broad-Spectrum Antibiotics
• Narrow-Spectrum Antibiotics
Formulation Types Covered:
• Single-Dose Vials
• Multi-Dose Vials
• Infusion Bags
• Pre-filled Syringes
Route of Administrations Covered:
• Intravenous (IV)
• Subcutaneous (SC)
• Intramuscular (IM)
Indications Covered:
• Respiratory Infections
• Urinary Tract Infections
• Skin and Soft Tissue Infections
• Hospital-Acquired Infections
• Intra-abdominal Infections
• Surgical Site Infections
• Sepsis and Bloodstream Infections
• Other Applications
End Users Covered:
• Hospitals
• Home Healthcare
• Specialty Clinics
• Ambulatory Surgical Centers
• Other End Users
Regions Covered:
• North America US Canada Mexico
• Europe Germany UK Italy France Spain Rest of Europe
• Asia Pacific Japan China India Australia New Zealand South Korea Rest of Asia Pacific
• South America Argentina Brazil Chile Rest of South America
• Middle East & Africa Saudi Arabia UAE Qatar South Africa Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
200 Pages
- 1 Executive Summary
- 2 Preface
- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
- 2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions
- 3 Market Trend Analysis
- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 End User Analysis
- 3.7 Emerging Markets
- 3.8 Impact of Covid-19
- 4 Porters Five Force Analysis
- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry
- 5 Global Parenteral Antibiotics Market, By Drug Class
- 5.1 Introduction
- 5.2 Penicillins
- 5.3 Macrolides
- 5.4 Cephalosporins
- 5.5 Glycopeptides
- 5.6 Carbapenems
- 5.7 Aminoglycosides
- 5.8 Other Drug Classes
- 6 Global Parenteral Antibiotics Market, By Spectrum of Activity
- 6.1 Introduction
- 6.2 Broad-Spectrum Antibiotics
- 6.3 Narrow-Spectrum Antibiotics
- 7 Global Parenteral Antibiotics Market, By Formulation Type
- 7.1 Introduction
- 7.2 Single-Dose Vials
- 7.3 Multi-Dose Vials
- 7.4 Infusion Bags
- 7.5 Pre-filled Syringes
- 8 Global Parenteral Antibiotics Market, By Route of Administration
- 8.1 Introduction
- 8.2 Intravenous (IV)
- 8.3 Subcutaneous (SC)
- 8.4 Intramuscular (IM)
- 9 Global Parenteral Antibiotics Market, By Indication
- 9.1 Introduction
- 9.2 Respiratory Infections
- 9.3 Urinary Tract Infections
- 9.4 Skin and Soft Tissue Infections
- 9.5 Hospital-Acquired Infections
- 9.6 Intra-abdominal Infections
- 9.7 Surgical Site Infections
- 9.8 Sepsis and Bloodstream Infections
- 9.9 Other Applications
- 10 Global Parenteral Antibiotics Market, By End User
- 10.1 Introduction
- 10.2 Hospitals
- 10.3 Home Healthcare
- 10.4 Specialty Clinics
- 10.5 Ambulatory Surgical Centers
- 10.6 Other End Users
- 11 Global Parenteral Antibiotics Market, By Geography
- 11.1 Introduction
- 11.2 North America
- 11.2.1 US
- 11.2.2 Canada
- 11.2.3 Mexico
- 11.3 Europe
- 11.3.1 Germany
- 11.3.2 UK
- 11.3.3 Italy
- 11.3.4 France
- 11.3.5 Spain
- 11.3.6 Rest of Europe
- 11.4 Asia Pacific
- 11.4.1 Japan
- 11.4.2 China
- 11.4.3 India
- 11.4.4 Australia
- 11.4.5 New Zealand
- 11.4.6 South Korea
- 11.4.7 Rest of Asia Pacific
- 11.5 South America
- 11.5.1 Argentina
- 11.5.2 Brazil
- 11.5.3 Chile
- 11.5.4 Rest of South America
- 11.6 Middle East & Africa
- 11.6.1 Saudi Arabia
- 11.6.2 UAE
- 11.6.3 Qatar
- 11.6.4 South Africa
- 11.6.5 Rest of Middle East & Africa
- 12 Key Developments
- 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
- 12.2 Acquisitions & Mergers
- 12.3 New Product Launch
- 12.4 Expansions
- 12.5 Other Key Strategies
- 13 Company Profiling
- 13.1 Pfizer Inc.
- 13.2 Sandoz
- 13.3 Merck & Co., Inc.
- 13.4 Spero Therapeutics
- 13.5 Johnson & Johnson
- 13.6 Astellas Pharma Inc.
- 13.7 GlaxoSmithKline plc
- 13.8 Entasis Therapeutics
- 13.9 Sanofi
- 13.10 F. Hoffmann-La Roche Ltd
- 13.11 Novartis AG
- 13.12 Bristol-Myers Squibb
- 13.13 Bayer AG
- 13.14 Eli Lilly and Company
- 13.15 Abbott Laboratories
- List of Tables
- Table 1 Global Parenteral Antibiotics Market Outlook, By Region (2024-2032) ($MN)
- Table 2 Global Parenteral Antibiotics Market Outlook, By Drug Class (2024-2032) ($MN)
- Table 3 Global Parenteral Antibiotics Market Outlook, By Penicillins (2024-2032) ($MN)
- Table 4 Global Parenteral Antibiotics Market Outlook, By Macrolides (2024-2032) ($MN)
- Table 5 Global Parenteral Antibiotics Market Outlook, By Cephalosporins (2024-2032) ($MN)
- Table 6 Global Parenteral Antibiotics Market Outlook, By Glycopeptides (2024-2032) ($MN)
- Table 7 Global Parenteral Antibiotics Market Outlook, By Carbapenems (2024-2032) ($MN)
- Table 8 Global Parenteral Antibiotics Market Outlook, By Aminoglycosides (2024-2032) ($MN)
- Table 9 Global Parenteral Antibiotics Market Outlook, By Other Drug Classes (2024-2032) ($MN)
- Table 10 Global Parenteral Antibiotics Market Outlook, By Spectrum of Activity (2024-2032) ($MN)
- Table 11 Global Parenteral Antibiotics Market Outlook, By Broad-Spectrum Antibiotics (2024-2032) ($MN)
- Table 12 Global Parenteral Antibiotics Market Outlook, By Narrow-Spectrum Antibiotics (2024-2032) ($MN)
- Table 13 Global Parenteral Antibiotics Market Outlook, By Formulation Type (2024-2032) ($MN)
- Table 14 Global Parenteral Antibiotics Market Outlook, By Single-Dose Vials (2024-2032) ($MN)
- Table 15 Global Parenteral Antibiotics Market Outlook, By Multi-Dose Vials (2024-2032) ($MN)
- Table 16 Global Parenteral Antibiotics Market Outlook, By Infusion Bags (2024-2032) ($MN)
- Table 17 Global Parenteral Antibiotics Market Outlook, By Pre-filled Syringes (2024-2032) ($MN)
- Table 18 Global Parenteral Antibiotics Market Outlook, By Route of Administration (2024-2032) ($MN)
- Table 19 Global Parenteral Antibiotics Market Outlook, By Intravenous (IV) (2024-2032) ($MN)
- Table 20 Global Parenteral Antibiotics Market Outlook, By Subcutaneous (SC) (2024-2032) ($MN)
- Table 21 Global Parenteral Antibiotics Market Outlook, By Intramuscular (IM) (2024-2032) ($MN)
- Table 22 Global Parenteral Antibiotics Market Outlook, By Indication (2024-2032) ($MN)
- Table 23 Global Parenteral Antibiotics Market Outlook, By Respiratory Infections (2024-2032) ($MN)
- Table 24 Global Parenteral Antibiotics Market Outlook, By Urinary Tract Infections (2024-2032) ($MN)
- Table 25 Global Parenteral Antibiotics Market Outlook, By Skin and Soft Tissue Infections (2024-2032) ($MN)
- Table 26 Global Parenteral Antibiotics Market Outlook, By Hospital-Acquired Infections (2024-2032) ($MN)
- Table 27 Global Parenteral Antibiotics Market Outlook, By Intra-abdominal Infections (2024-2032) ($MN)
- Table 28 Global Parenteral Antibiotics Market Outlook, By Surgical Site Infections (2024-2032) ($MN)
- Table 29 Global Parenteral Antibiotics Market Outlook, By Sepsis and Bloodstream Infections (2024-2032) ($MN)
- Table 30 Global Parenteral Antibiotics Market Outlook, By Other Applications (2024-2032) ($MN)
- Table 31 Global Parenteral Antibiotics Market Outlook, By End User (2024-2032) ($MN)
- Table 32 Global Parenteral Antibiotics Market Outlook, By Hospitals (2024-2032) ($MN)
- Table 33 Global Parenteral Antibiotics Market Outlook, By Home Healthcare (2024-2032) ($MN)
- Table 34 Global Parenteral Antibiotics Market Outlook, By Specialty Clinics (2024-2032) ($MN)
- Table 35 Global Parenteral Antibiotics Market Outlook, By Ambulatory Surgical Centers (2024-2032) ($MN)
- Table 36 Global Parenteral Antibiotics Market Outlook, By Other End Users (2024-2032) ($MN)
- Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.